Labor/HHS
This article was originally published in The Tan Sheet
Executive Summary
Appropriations bill amendment proposed by Sens. Orrin Hatch (R-Utah) and Tom Harkin (D-Iowa) Oct. 31 stipulates that of funds provided to Office of the General Counsel, "not less than $500,000 shall be used to provide legal support for enforcement of the labeling provisions" of DSHEA. Funding would complement an Oct. 25 amendment to the Ag Approps bill that calls for increased CFSAN investigations, compliance activities (1"The Tan Sheet" Oct. 29, In Brief). Labor/HHS amendment also stipulates publication of FDA supplement GMPs proposed rule "within 15 days" of bill enactment. NCCAM would receive $110 mil. in fiscal 2002 under S 1536, which is expected to pass the Senate this week...
You may also be interested in...
Dietary supplement enforcement
Language added to Agriculture Appropriations bill by Sens. Orrin Hatch (R-Utah) and Tom Harkin (D-Iowa) Oct. 25 would provide CFSAN with $1 mil. to "enhance enforcement of requirements under [DSHEA] related to the accuracy of product labeling, and the truthfulness and substantiation of claims." HR 2330 passed the Senate 91-5 with 36 amendments the same day and now is headed for a conference between the two chambers. Introducing the amendment, Hatch noted he and Harkin have become "increasingly alarmed over reports that unsafe or mislabeled dietary supplement products are being marketed." Hatch also expressed concern about the number of teenagers taking performance-enhancing products, adding "it is not clear they fall within the legal definition of dietary supplement"
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.